Incyte Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William J. Meury
- Full Time Employees
- 2,617
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1801 Augustine Cut-Off Wilmington DE United States of America 19803
- IPO Date
- Nov 4, 1993
- CIK
- 0000879169
- Website
- incyte.com
- Similar Companies
- Business
- Incyte Corporation (INCY) is a Wilmington, Delaware-based biopharmaceutical company founded in 2002 that discovers, develops, and commercializes proprietary medicines for oncology, inflammation, autoimmunity, and dermatology; it operates globally in North America, Europe, and Asia with over 2,500 employees focused on unmet medical needs. The company markets a diversified portfolio of approved products including Jakafi (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease; Opzelura (ruxolitinib) cream for atopic dermatitis and vitiligo; Pemazyre (pemigatinib) for cholangiocarcinoma and myeloid/lymphoid neoplasms; Monjuvi (tafasitamab-cxix) for relapsed or refractory diffuse large B-cell lymphoma; Tabrecta (capmatinib) for non-small cell lung cancer; Iclusig (ponatinib) for leukemia; and Olumiant (baricitinib) for rheumatoid arthritis and alopecia areata; it also advances a robust pipeline of clinical candidates discovered in-house targeting immunology, hematology-oncology, and inflammatory skin conditions. Recent developments include the 2024 acquisition of Escient Pharmaceuticals for $750 million to add first-in-class oral MRGPRX2 antagonists EP262 for hidradenitis suppurativa, prurigo nodularis, and other pruritic skin diseases and EP547 for pruritus in kidney and liver diseases; FDA approval of Niktimvo (axatilimab-csfr) with partner Syndax Pharmaceuticals in August 2024 for chronic graft-versus-host disease; relocation of over 300 Pennsylvania jobs to expanded downtown Wilmington headquarters by 2026 supporting more than 500 positions; and a 2025 roadmap featuring four potential product launches such as ruxolitinib XR and povorcitinib expansions, four pivotal trial readouts, seven proof-of-concept disclosures, and at least three Phase 3 initiations toward over 10 high-impact launches by 2030.
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
Here's Why Incyte (INCY) is a Strong Momentum Stock
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out
Here's Why Incyte (INCY) is a Strong Value Stock
Why Incyte (INCY) is a Top Growth Stock for the Long-Term
Inside Incyte's $120 Million AI For Drug Development Deal
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build
Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Why Incyte (INCY) is a Top Value Stock for the Long-Term